V-8303 Vatalanib, Dihydrochloride Salt, >99%

Related Terms : [CGP-79787] [PTK 787] [ZK222584]

  • Size
  • US $
  • £
  • ¥
  • 25 mg
  • 39
  • 35
  • 29
  • 4,100
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 68
  • 61
  • 51
  • 7,100
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 95
  • 85
  • 72
  • 10,000
  • Add to Cart Qty:
  • In stock
  • 250 mg
  • 106
  • 95
  • 80
  • 11,100
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 198
  • 178
  • 150
  • 20,700
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 364
  • 328
  • 276
  • 38,100
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 596
  • 537
  • 452
  • 62,400
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 419.73
  • C20H15ClN42HCl
  • [212141-51-0]
  • M.I. 14: 9939

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 10-20 mg/mL with warming; very poorly soluble in ethanol; soluble in water at 100 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

  • Vatalanib is a potent, selective, orally active inhibitor of the VEGFR tyrosine kinases VEGFR-1 (Flt-1, IC50 = 77 nM) and VEGFR-2 (FLK-1/KDR, IC50 = 37 nM), with slightly higher potency against the latter. At higher concentrations, other tyrosine kinases are also inhibited, including PDGFR-β (IC50 = 580 nM), c-KIT (IC50 = 730 nM), FLT-4 (IC50 = 660 nM) and c-FMS (IC50 = 1.4 µM). On the other hand, vatalanib is not active against the EGFR, c-SRC, v-ABL, and protein kinase Cα (IC50 > 10 µM). Wood, J.M., et al. "PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration." Cancer Res. 60: 2178-2189 (2000).
  • Vatalanib dose-dependently inhibits proliferation of MM cells and patient cells (IC50 = 1-5 µM), which are both sensitive and resistant to conventional therapy. Vatalanib increases the inhibitory effect of dexamethasone on growth of MM cells and can decrease the protective effect of interleukin 6 (IL-6) against dexamethasone-induced apoptosis. Vatalanib (1 µM) also inhibits VEGF-induced migration of MM cells across an extracellular matrix. Importantly, vatalanib also blocks the increased MM cell proliferation and increased IL-6 and VEGF secretion in cultures of MM cells adherent to bone marrow stem cells. Lin, B., et al. "The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment." Cancer Res. 62: 5019-5026 (2002).
  • Vatalanib inhibited VEGF-induced phosphorylation (IC50's of 17 nM and 34 nM for HUVECs and CHO cells, respectively), blocked thymidine incorporation induced by VEGF in HUVECs (IC50 = 7.1 nM), prevented VEGF-induced HUVEC migration dose dependently (IC50 = 58 nM), and inhibited tumor cell proliferation with an IC50 of 17 µM and 18 µM for A431 and DU145 cells, respectively and sprout formation in rat aortas (IC50 = 675 nM). Wood, J.M., et al. "PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration." Cancer Res. 60: 2178-2189 (2000).
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
324